Xconomy | Boston - Business + Technology in the Exponential Economy

Imaging Agent for Early Detection of Heart Disease, From Molecular Insight, Reaches Goal
Molecular Insight Pharma Director Barlow Resigns Over Rift with Board
Molecular Insight Preps for Pivotal Trial of Heart Attack Warning Sign Detector
Biogen Idec Rebuts Icahn Attack, GlaxoSmithKline Quietly Spins Off Tempero Pharmaceuticals, Knome Launches Cheaper Sequencing Service, & More Boston-Area Life Sciences News
Molecular Insight Names CEO, Chair

Molecular Insight Names Peters CEO

Molecular Insight Pharmaceuticals (NASDAQ:MIPI) reports today it has a new president and CEO, Daniel Peters, who was previously president of the diagnostics division of GE Healthcare. Peters takes over the chief executive role from Molecular co-founder John Babich, who is staying with the Cambridge, MA-based firm as chief scientific officer in charge of research and development. Molecular is developing an imaging agent, Zemiva, for diagnosing lack of blood flow to the heart, or cardiac ischemia.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.

Comments | Reprints | Share: